Export 1712 results:
Autore Titolo Tipo [ Anno(Asc)]
Filtri: First Letter Of Last Name è S  [Clear All Filters]
2013
De Rocco D, Zieger B, Platokouki H, Heller PG, Pastore A, Bottega R, Noris P, Barozzi S, Glembotsky AC, Pergantou H, Balduini CL, Savoia A, Pecci A. MYH9-related disease: five novel mutations expanding the spectrum of causative mutations and confirming genotype/phenotype correlations. Eur J Med Genet 2013;56(1):7-12.
Colombatti R, Perrotta S, Samperi P, Casale M, Masera N, Palazzi G, Sainati L, Russo G. Organizing national responses for rare blood disorders: the Italian experience with sickle cell disease in childhood. Orphanet J Rare Dis 2013;8:169.
Colombatti R, Perrotta S, Samperi P, Casale M, Masera N, Palazzi G, Sainati L, Russo G. Organizing national responses for rare blood disorders: the Italian experience with sickle cell disease in childhood. Orphanet J Rare Dis 2013;8:169.
Tisato V, Toffoli B, Monasta L, Bernardi S, Candido R, Zauli G, Secchiero P. Patients affected by metabolic syndrome show decreased levels of circulating platelet derived growth factor (PDGF)-BB. Clin Nutr 2013;32(2):259-64.
Zannin ME, Birolo C, Gerloni VM, Miserocchi E, Pontikaki I, Paroli MP, Bracaglia C, Shardlow A, Parentin F, Cimaz R, Simonini G, Falcini F, Corona F, Viola S, De Marco R, Breda L, La Torre F, Vittadello F, Martini G, Zulian F. Safety and efficacy of infliximab and adalimumab for refractory uveitis in juvenile idiopathic arthritis: 1-year followup data from the Italian Registry. J Rheumatol 2013;40(1):74-9.
Zannin ME, Birolo C, Gerloni VM, Miserocchi E, Pontikaki I, Paroli MP, Bracaglia C, Shardlow A, Parentin F, Cimaz R, Simonini G, Falcini F, Corona F, Viola S, De Marco R, Breda L, La Torre F, Vittadello F, Martini G, Zulian F. Safety and efficacy of infliximab and adalimumab for refractory uveitis in juvenile idiopathic arthritis: 1-year followup data from the Italian Registry. J Rheumatol 2013;40(1):74-9.
2012
Giersiepen K, Lelgemann M, Stuhldreher N, Ronfani L, Husby S, Koletzko S, Korponay-Szabó IR. Accuracy of diagnostic antibody tests for coeliac disease in children: summary of an evidence report. J Pediatr Gastroenterol Nutr 2012;54(2):229-41.
Secchiero P, Rimondi E, di Iasio MGrazia, Voltan R, Gonelli A, Zauli G. Activation of the p53 pathway induces α-smooth muscle actin expression in both myeloid leukemic cells and normal macrophages. J Cell Physiol 2012;227(5):1829-37.
Barbi E, Longo G, Berti I, Matarazzo L, Rubert L, Saccari A, Lenisa I, Ronfani L, Radillo O, Ventura A. Adverse effects during specific oral tolerance induction: in home phase. Allergol Immunopathol (Madr) 2012;40(1):41-50.
Barbi E, Longo G, Berti I, Neri E, Saccari A, Rubert L, Matarazzo L, Montico M, Ventura A. Adverse effects during specific oral tolerance induction: in-hospital "rush" phase. Eur Ann Allergy Clin Immunol 2012;44(1):18-25.
Pecci A, Biino G, Fierro T, Bozzi V, Mezzasoma A, Noris P, Ramenghi U, Loffredo G, Fabris F, Momi S, Magrini U, Pirastu M, Savoia A, Balduini C, Gresele P. Alteration of liver enzymes is a feature of the MYH9-related disease syndrome. PLoS One 2012;7(4):e35986.
Bosco R, Rabusin M, Voltan R, Celeghini C, Corallini F, Capitani S, Secchiero P. Anti-leukemic activity of dasatinib in both p53(wild-type) and p53(mutated) B malignant cells. Invest New Drugs 2012;30(1):417-22.

Amministrazione Trasparente